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Abstract
Background: Cell-based therapies can be used to treat neurological diseases and spinal cord injuries. The aim
of this study was to assess the clinical outcome of bone marrow derived mononuclear cells (BM-MNCs) trans-
plantation in patients with spinal cord injuries.
Methods: Following a systematic review to detect clinical intervention studies, a meta-analysis was done for
pooling data to estimate the outcome of BM-MNCs transplantation. The percentage of the patients with im-
proved ASIA scale from one grade to a higher grade was defined as the main outcome. By considering the study
design and outcome measurement, two reviewers independently extracted the data.
Results: Eight relevant primary studies were found; seven qualified studies, with a combined total of 328 pa-
tients were assessed by meta-analysis, including 314 ASIA-A, 13 ASIA-B, 94 cervical, 227 thoracic and 60
acute injuries. The percentage of the patients’ improvement was tested by meta-analysis through random and
fixed models. The overall percentage of all patients’ improved ASIA scale after a one- year follow-up (95%
CIs) was 43 (0.27-0.59).
Conclusion: Data from published trials revealed that encouraging results were achieved by autologous BM-
MNCs for the treatment of spinal cord injury. However, the number of clinical trials included in the systematic
review was too limited to reach a definite conclusion. More qualified clinical trials with standardized methods
are needed to truly justify the outcome of this therapeutic modality in SCI patients.
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Introduction
Spinal Cord Injury (SCI) occurs with a
worldwide incidence of 15–40 cases per
million people annually (1). Epidemiologi-
cal data concerning the global prevalence
of SCI is inaccessible. Also, it is appraised
that more than 130,000 patients suffer from
SCI per year. The mean age of spinal cord
injury patients is 30 years, demonstrating
that it disables persons in the prime of their
lives. The high rate of incidence in adoles-
cent groups is reasoned to the road acci-
dents and sports related damages (2).Up to
now, there is no cure available for these
individuals, and SCI usually leads to im-
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lack of internationally accepted scientific
evidences, cell-based therapies offer great
promise for many currently intractable
conditions including neurological disorders.
Frequently mentioned targets include neu-
rological diseases and spinal cord injury
(5). Different cell types have been studied
in animal models and clinical trials. The
bone marrow derived from mononuclear
cells (BM-MNCs) is extracted from the
bone marrow directly, or it is derived via
mobilization into the peripheral blood using
granulocyte colony-stimulating factor
(GCSF) (6). BM-MNCs are the most com-
mon cell population used in neuropatholog-
ic insults. These cells have many ad-
vantages including easy and rapid isolation
with minimal manipulation, ample cell
number, low processing costs and a mini-
mally invasive bone marrow harvest proce-
dure (7). BM-MNCs have been reported to
promote repair and regeneration of nervous
tissue within the central and peripheral
nervous system (8). It seems that BM-MNC
can facilitate recovery from SCI by promot-
ing remyelinating spared white matter
tracts or intensifying axonal growth (9).
However, the transdifferentiation of BM
cells into myelin cells is an area of great
controversy, and there is no convulsive ev-
idence that these cells do this process with-
out extensive genetic and epigenetic ma-
nipulation.
Although the results of pre-clinical stud-
ies recommend that BM-MNCs could be
used as a potential therapy for SCI, (10)
they have not clearly indicated whether the-
se cells have therapeutic advantages in SCI
patients. Since BM-MNCs transplantation
has been considered as a novel intervention
in clinical trials for SCI, it has not been sci-
entifically proven to be safe and effective.
This systematic review investigates the
clinical outcome of BM-MNCs transplanta-
tion for patients with traumatic SCI. The
objective was to determine whether BM-
MNC transplantation can increase ASIA
scale, which is a valid and useful tool for
determining the function maintained by a




We performed PICOS framework (De-
termining patient, problem or population,
intervention, comparison and outcome) to
define the main concepts of the research
questions.
Patient: People with Spinal Cord Injury
Intervention: Bone Marrow Transplanta-
tion
Comparison: No Treatment
Outcome: Improvement in the ASIA
Score
Computerized databases were searched
on 28 October 2012. To retrieve both origi-
nal and secondary related studies, we used
a sensitive librarian-assisted search strategy
in the last available version of the three fol-
lowing databases at the time of the search:
MEDLINE via Ovid SP (1948 to 28 Octo-
ber 2012), EMBASE via Ovid SP (1989 to
27 October 2012) and CENTRAL via Ovid
SP (September 2012). The search was lim-
ited to the English language. Search was
updated on May 2013; however, no new
records were found.  Because of the low
number of results in the primary search, we
applied a sensitive search strategy to re-
trieve a suitable number of records and
minimize any missing of possible related
records. Therefore, we included only prob-
lem and intervention in PICOS structure of
the formulated question to achieve higher
sensitivity, and we did not limit our results
to humans and particular types of study de-
signs. The database search was completed
with a search of RCTs (Randomize Control
Trials) registries and reviewing of the ref-
erence lists of the included studies along
with citations. The following search strate-
gy was developed for MEDLINE via Ovid
SP and was then adapted to other resources:
I: Spinal Cord Injury
1. exp spinal cord injuries/
2. (((spinal or central or cervical or me-
dulla$) adj3 cord) adj3 (trauma$ or injur$
or syndrome or lesion or compress$ or
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5. (autonom$ adj3 (dysreflexia$ or hy-
per?reflexia$)).tw,ot.
6. myelopath$.tw,ot.
7. (conus medullaris syndrome).tw,ot.
8. or/1-7
II: Bone Marrow Transplantation
9. bone marrow transplantation/
10. bone marrow purging/
11. exp stem cell transplantation/ and
(bone marrow).tw,ot.
12. ((bone marrow) adj6 (transplant$ or
graft$ or purg$ or (cell adj (transfer or re-
mov$)) or rescu$ or transfus$)).tw,ot.
13. ((((stem cell) or cord) adj (trans-
plant$ or graft$ or purg$ therap$)) and
(bone marrow)).tw,ot.
14. or/9-13
III: I and II
15. 8 and 14
Inclusion criteria
All those clinical trials which measured
neurological assessment as ASIA scale pre-
and post-transplantation or those which in-
cluded participants with traumatic SCI
(cervical or thoracic level) as well as ASIA
(American Spinal Injury Association) scale
A or B at baseline were included in this re-
view.
Exclusion criteria
Animal studies were excluded in this re-
view. Other studies that did not report
ASIA score as a clinical outcome along
with those studies which considered other
types of bone marrow derived cells or
mixed cell population (BM-MSCs + BM-
MNCs) as well as case reports were ex-
cluded from this review.
Subgroups
This review determined three subgroups
on the basis of impairment scale, level of
injury and duration of SCI. The ICCP (In-
ternational Campaign for Cures for spinal
cord injury Paralysis) panel guideline men-
tioned that these variables can influence
spontaneous recovery rate. However, a
clinical trial considering ASIA -A patients
showed less spontaneous improvement over
time (18). This review analyzed patients
with complete and incomplete ASIA sepa-
rately. In addition, the duration of SCI in
terms of acute and chronic injuries was de-
fined, and the level of injury was divided
into cervical and thoracic injury.
Data extraction
Data extraction was conducted by two in-
dependent researchers of the study (M-Y
and HR-A). Data pertaining to the number
of the enrolled patients, injury types and
levels, type and dose of cell transplants,
duration of the follow ups and clinical out-
comes with confidence intervals were ex-
tracted from the papers. We defined the
percentage of the patient’s improvement
from ASIA scale A to B/C or ASIA scale B
to C/D as a clinical outcome after a one-
year follow-up. It should be noted that a
clinical trial with a small size effect may
need a more accurate outcome measure
such as a statistically mean change in the
motor and sensory scores (19). Therefore,
we reported the mean change of the motor
score and sensory score (light touch and
Pinprick) at the time of the transplant and at
the end of the last follow-up as a functional
outcome in three studies (10, 14, 16). These
studies reported the details of motor and
sensory scores along with the ASIA scale.
The confidence interval and lower and up-
per limits were not reported directly, so we
calculated and recorded them using other
indices which were based on formulas.
Synthesis of the results
Meta-analysis was performed using the
STATA statistical package version 11.
First, we assessed the heterogeneity be-
tween the studies by Chi-squared test
(P<0.1 as meaningful). We used random or
fixed model for pooling the percentage of
improvement and 95% confidence intervals
in case of heterogeneous and homogenous
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less than 0.05 were regarded significant.
The subgroups were determined based on
the patients’ injury type (impairment scale,
level and stage of injury). ASIA-A, ASIA-
B, cervical, thoracic and acute patients
were regarded as subgroups. Chronic sub-
groups were excluded from the meta- anal-
ysis because this subgroup included only
one study.  Due to the different characteris-
tics of each subgroup after excluding the
chronic group from the analysis, we had to
pool the data from the acute group sepa-
rately, not acute versus chronic; otherwise,
the pooled estimate would have led to an
inability in reaching a firm conclusion




The search identified 594 studies, among
which 122 were duplicates (Fig. 1). Titles
and abstracts of the obtained articles were
assessed for relevancy by two researchers
independently (M-Y, HR-A). Any disa-
greements were resolved by consensus or
discussion with the authors. After screening
the titles and abstracts, 17 studies were de-
termined as eligible (BM-MNC transplanta-
tion, in which the standard neurological
outcome had been reported). The full texts
of the relevant articles were checked for
eligibility criteria after investigating the full
reports, and consequently nine studies were
excluded. Finally, eight studies with a total
number of 337 participants were evaluated
to find the outcome of BM-MNC transplant
in patients with SCI (Table 1) (12–17).
Moreover, seven studies were included in
the meta- analysis.
With respect to the quality assessment, all
clinical trials had a high risk of bias; specif-
ically, seven of eight studies were non-
randomized. Moreover, the details of ran-
domization methods were unclear in the
remaining studies. Since it is difficult to
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blind therapists to use stem cell transplant,
none of the clinical trials reported alloca-
tion concealment or blinding. With regards
to the incomplete data, all trials had a low
risk of bias. Overall, two out of 337 pa-
tients failed to participate in the follow-up
durations.
Meta analysis
We ended up with eight studies in the
systematic review, one of which was ex-
cluded from our analysis because of 100%
improvement (No variation) (13). The re-
maining studies had a combined total of
328 patients. Our findings revealed a con-
siderable heterogeneity among these studies
(X2=36.1, p<0.0001, I2=83.6%). Also, the
results of the meta- analysis using a random
model revealed an estimate of 0.428 (95%
CI = (0.268, 0.589)) for the proportion of
the improvement which was statistically
significant (p<0.0001). Although the meta-
analysis in the subgroups of patients with
BM-MNCs transplantation in ASIA-B at
baseline resulted in homogeneity between
the studies, a considerable heterogeneity
Table 1. Published BM-MNCs Transplantation Trials for SCI
Reference Participant Trans-
plant



















19.6-275 75 75 0 0 75 75 0 - 1 year Follow-up. 3 pa-
tient of 4 show neurologi-
cal improvement and
none of the patients suf-
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20-67 100 100 0 100 100 0 100 - 1 year Follow-up. All of
the patients showed im-
proved neurological func-
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of life scores .no cases of
tumorformation, infec-
















200 47 52 50 50 55 47 0 - 3-11 month Follow-up.
The ASIA scale of the
group had improved in 7
patients from grade A to
C, in 3 patients from
grade A to B, and in 1
















1 31 31 42 34 31 0 31 - 3-21 month Follow-up.
One-third of spinal cord
injury patients had im-
proved .motor and senso-
ry change happened in
32.6% of patients. No
complications or side
effect were reported, ex-
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was observed among them by considering
ASIA-A, acute, cervical and thoracic sub-
groups of patients. Table 2 demonstrates
the number of patients in each subgroup
and the estimated pooled proportion of im-
provement as well as the results of hetero-
geneity tests. The meta- analysis revealed
that the percentage of patient improvement
(95% CIs) was 0.41 (0.25-0.58) for patients
with ASIA scale A at the baseline, 0.37
(0.11-0.63) for patients with ASIA scale B
at the baseline, 0.53 (0.31-0.74) for patients
in acute stage, 0.43 (0.18-0.67) for patients
with cervical injury level and 0.50 (0.28-
0.72) for patients with thoracic injury level.
ASIA impairment scale in SCI clinical
trial was considered as a clinical outcome.
However, considering the functional out-
Table 1. Published BM-MNCs Transplantation Trials for SCI
Study Participant Trans-
plant
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200 20 20 0 17 25 21 0 7 10 month Follow-
up.7 patients of 35
patients in trans-
plant group and one









A*= ASIA A patient, B**= ASIA B patient, C ʸ =Cervical level, T^= Thoracic Level, Ac ʰ= Acute, Ch˅=Chronic, CG ʳ=Control Group.
Table 2. Results of the Subgroups’ Meta- Analysis and Heterogeneity Tests
Subgroups No. of Studies No. of Patients Heterogeneity Pooled Estimate
X2 P-value I2 Proportion (95% CI) P-value
ASIA-A 7 314 38.8 <0.0001 84.6 0.419 (0.254, 0.585) <0.0001
ASIA-B 3 13 0.54 0.763 0 0.373 (0.115, 0.630) <0.0001
Acute 6 60 14.92 0.011 66.5 0.530 (0.313, 0.746) <0.0001
Cervical 5 94 22. 8 <0.0001 82.5 0.432 (0.189, 0.674) <0.0001
Thoracic 5 227 17.04 0.002 76.5 0.501 (0.281, 0.722) <0.0001
X2: Heterogeneity chi-squared
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come (motor and sensory scores) might al-
so be useful in these trials. As a result of
the mean change of the motor and sensory
scores, three qualified studies conducted on
32 patients were assessed (Table 3). In the
other trials, the details of the scores were
not reported.
Discussion
The aim of this systematic review was to
evaluate the clinical outcome of BM-MNCs
transplant in SCI. The outcome measures
Fig. 2. Forest Plot for Overall Percentage of Patient Improved ASIA Scale
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were to obtain improvement in ASIA scale.
The overall percentage of improvement be-
tween 328 patients was 43% .There was a
considerable heterogeneity among these
studies I2=83.6% (Fig. 2). Meta- analysis
was performed for each subgroup to
achieve better results. Clinical outcome in
patients who had ASIA scales A and B
showed that the percentage of improvement
in patients who had ASIA scale A at base-
line (41%) was more than ASIA scale B
(37%) (Table 2). Considerable differences
between the number of patients in the sub-
groups of ASIA-A and ASIA-B might have
Fig. 4. Forest Plot for Overall Percentage of Patients with ASIA-B Improved ASIA Scale
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led to this result because the likelihood of
improvement in patients with incomplete
impairment should be more than the com-
plete functional impairment (19). In addi-
tion, there was homogeneity between the
studies that included patients with ASIA-B
at baseline in contrast with studies that in-
cluded ASIA –A at baseline (Figs. 3, 4). In
comparison with the cervical and lumbar
segment, cell transplantation in a thoracic
segment might be less likely to affect a sig-
nificant outcome. However, the potential
risk of adverse effects which may result
from the manipulation of cervical and lum-
bar spinal cord regions is higher. Therefore,
a potential trial should weigh the ad-
Fig. 6. Forest Plot for Overall Percentage of Cervical Patient Improved ASIA Scale
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vantages and risks of treating cervical ver-
sus thoracic injuries (18). Thoracic cases
were included for safety concerns in most
of phase I/II trials. The result of the meta-
analysis revealed a considerable heteroge-
neity in both groups (Figs. 6, 7). In addi-
tion, improvement in ASIA scale occurred
in the patients with thoracic level (50%)
more than cervical level (43%) (Table 2),
and this may be due to the higher number
of thoracic cases in this review. To assess
the potentially beneficial effects of experi-
mental treatments in SCI trials, mean
changes in motor and sensory scores can be
a more reliable efficacy index than the con-
version of ASIA scale (21). In our review,
just three out of eight studies (10, 14, 16)
reported the details of ASIA motor and
sensory scores. Although the percentage of
patients with improved ASIA scores were
10% in one of these studies (16), the pooled
mean change of motor, light touch and Pin-
prick scores in patients of this study signif-
icantly increased after intervention (Table
3). Another clinical trial assessed the quali-
ty of life score as Barthel Index. Geffner et
al. (14) investigated different routes of
transplant directly into the spinal cord, the
spinal canal and intravenously and ob-
served improvements in Barthel Index of
all the patients. Considering the fact that
the quality of life assessment in spinal cord
injury is significant, it might be helpful to
use this tool as a secondary outcome
(19).The authors suggest that quality of life
assessment be considered as a generic out-
come for SCI cell transplantation trials. On-
ly in one clinical trial a control group was
included. In this trial, the intervention
group demonstrated more improvement in
ASIA scale than the control group. Yoon
and colleagues (17) regarded 13 patients
treated with conventional decompression
and fusion surgery as the control group. In
this trial, 20 % of the treatment group and 7
% of the control patients indicated an im-
proved neurological function. Co-
administration of granulocyte macrophage-
colony stimulating factor (GM-CSF) has
been applied in two studies. Yoon et al.
(17) stated that the administration of GM-
CSF for SCI patients may result in the pro-
gress of neurologic functions without any
adverse effect. Recently, several research-
ers revealed that GM-CSF stimulates mi-
croglial cells to produce neurotrophic cyto-
kines such as BDNF (22). In addition, Park
and colleagues (20) believed that GM-CSF
enhances the activity of the patients’ bone
marrow and increases the number of BM
derived stem cells in the circulating periph-
eral blood. However, GM-CSF administra-
tion induced fever, pain and leukocytosis in
this trial. Regarding dynamic pathophysio-
logical and multifactorial nature of SCI and
its consequences, the success of future cell
therapy might likely depend on the in-
formed co-administration of combinatorial
stem cell transplantation, pharmacological
and rehabilitation therapies (4). This review
demonstrated that BM-MNCs transplanta-
tion is a relatively safe intervention without
serious adverse events. In comparison with
mesenchymal stem cells or other cell types,
BM-MNCs can be easily obtained and iso-
lated in a short time just before transplanta-
tion and do not require in vitro expansion.
This reduces processing costs and minimiz-
es the risks of contamination (23).
There were many restrictions in drawing
a certain conclusion on the outcome of
BM-MNCs transplantation in this review.
As clinical trial in stem cell therapy is a
new method and there is no sufficient liter-
ature on stem cell therapy due to the ethical
issues and other limitations, we did not
consider quality assessment and publication
bias of the included studies in this analysis.
The included trials in this review did not
consider control groups or blinded assess-
Table 3. Mean Change of Motor and Sensory Score in 3 Clinical Trials
Study ID Patient Motor Light Touch Pinprick p
Geffner et al [11] 8 9.87±7.3 13.37±9.8 15±9.2 <0.0001
Sykova et al [15] 19 4.7±13 5.9±21.9 5.1±14.1 <0.0001
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ments, and this might have led to an over-
estimation of the overall outcome (24).
Although the quality assessment of the trial
tools presented good correlation, the results
of one study which evaluated the impact of
quality assessment in the meta- analysis
showed that in systematic reviews with the
same direction of effect, the quality as-
sessment may not significantly change the
results (25). Since most of the included
studies in this review demonstrated some
degrees of improvement, waiving the quali-
ty of trials may not cause significant
changes.
Conclusion
BM-MNCs transplantation in spinal cord
injury seems to be feasible, safe and have a
good degree of outcome improvement. Alt-
hough most of the studies showed promis-
ing results, more qualified randomized con-
trolled trials should be conducted to exam-
ine the efficacy and appropriate dosage of
BM-MNCs for patients with spinal cord
injuries.
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